IMA vs ARQT vs SRZN vs DERM vs SKIN

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -77. 1% for ImageneBio Inc (IMA). Analysts rate Arcutis Biotherapeutics, Inc. (ARQT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcutis Biotherapeutics, Inc.

(ARQT) delivered a total return of -16. 2%, compared to -96. 7% for ImageneBio Inc (IMA). Over 10 years, the gap is even starker: ARQT returned +11. 8% versus IMA's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ImageneBio Inc (IMA) is the lower-risk stock at 0.

83β versus Journey Medical Corporation's 1. 98β — meaning DERM is approximately 138% more volatile than IMA relative to the S&P 500. On balance sheet safety, Journey Medical Corporation (DERM) carries a lower debt/equity ratio of 0% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus -77. 1% for ImageneBio Inc (IMA). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -954. 9% for ImageneBio Inc. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Beauty Health Company (SKIN) is the more profitable company, earning -3.

2% net margin versus -69. 6% for Surrozen, Inc. — meaning it keeps -3. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARQT leads at -3. 3% versus -60. 6% for IMA. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Journey Medical Corporation (DERM) trades at 97.

5x forward P/E versus 122. 5x for Arcutis Biotherapeutics, Inc. — 24. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SKIN: 134. 0% to $1. 53.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ImageneBio Inc (IMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

83)). Journey Medical Corporation (DERM) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMA: -98. 6%, DERM: -33. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IMA (Healthcare) and ARQT (Healthcare) and SRZN (Healthcare) and DERM (Healthcare) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IMA is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; SRZN is a small-cap quality compounder stock; DERM is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.